2019 American Transplant Congress
The Effects of Anti-BAFF Monoclonal Antibody in the HLA-A2 Sensitized Mouse Model
*Purpose: B-cell activating factor (BAFF) is a cytokine that plays a role in the survival, proliferation and differentiation of B-cells. The aim of this study…2019 American Transplant Congress
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Solid Organ Transplant Recipients at an Academic Medical Center
Center for Transplantation, University of California, San Diego Health System, La Jolla, CA
*Purpose: In the United States, the incidence of Clostridium difficile infection (CDI) has increased remarkably and remains a significant burden in the solid organ transplant…2019 American Transplant Congress
Intravenous Immunoglobulin Significantly Reduces Bioavailability of Concomitantly Administered Anti-C5 Monoclonal Antibodies
*Purpose: Awareness of drug-drug interactions is critical in management of organ transplant recipients. However, there is little understanding of the possibility of biologic agents interfering…2019 American Transplant Congress
Characterization of HLA Antibodies by C3d Assay and IgG Subclasses in Sensitized Kidney Transplant Patients
Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico
*Purpose: To determine the detection rate of IgG subclasses (IgGsc) and C3d-binding HLA-antibodies (abs) in a cohort of highly sensitized kidney transplant patients.*Methods: We evaluated,…2019 American Transplant Congress
Rituximab Protects against Development of Atherosclerotic Cardiovascular Disease after Kidney Transplantation, a Propensity Matched Analysis
Severance hospital, Seoul, Korea, Republic of
*Purpose: Recent studies have implicated B cells in atherosclerosis and have verified the atheroprotective effect of rituximab. We sought to explore the effects of rituximab…2017 American Transplant Congress
Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: ~30% of HS patients fail to respond to DES with IVIG+rituximab. IL6/IL-6R signaling is critical for B-cell differentiation to plasmablasts and IgG production. Tocilizumab…2017 American Transplant Congress
Combination αCD28+αCD40 Costimulation Blockade Attenuates Acute and Chronic Rejection in Non-Human Primates.
University of Maryland School of Medicine, Baltimore, MD
Purpose: Monotherapy using αCD28 or αCD40 antibodies significantly prolongs graft survival but does not induce tolerance in non-human primates (NHP). Here, we evaluate the relative…2017 American Transplant Congress
Daratumumab for Severe Refractory Proliferative Glomerulonephritis with Monoclonal Immune Deposits (PGNMID).
Introduction-We report as case of refractory PGNMID treated succesfully with anti-CD38 antibody (Daratumumab). Case report-65 year old male with ESRD attributed to to post infectious…2017 American Transplant Congress
Does Blockade of ICOS/ICOS-L Pathway Act Synergistically with αCD40 Costimulation Pathway Blockade?
University of Maryland School of Medicine, Baltimore, MD
Purpose: Inducible costimulator (ICOS) on T cells enhances basic T cell responses to foreign antigen, and increased ICOS expression is detected in association with pathogenic…2017 American Transplant Congress
Delayed Calcineurin Inhibitor Introduction and Long Term Renal Outcomes in Liver Transplant Recipients Receiving Basiliximab Induction.
BACKGROUND Basiliximab may be used to delay the initation of calcineurin inhibitors (CNI) in patients with renal injury after liver transplantation (LT). The optimal time…
American Transplant Congress abstracts